Rosa Rodríguez-Monguió

Author

University of Massachusetts Amherst ORCID

Also Known As

Candy Tsourounis, Catherine Devoe, R Rodriguez-Monguio, R Rodriguez-monguio, R. Rodriguez-Monguio, Rodriguez-Monguio, Rosa, Rosa Rodriguez-Monguio, Rosa Rodriguez-Monguio (814173), Rosa Rodriguez-Monguio, PhD, MS, Rosa Rodriguez-monguio

169

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

University of Massachusetts Amherst Massachusetts College of Pharmacy and Health Sciences University of California, San Francisco Chapman University University of California System

About

Rosa Rodríguez-Monguió is an author at University of Massachusetts Amherst specializing in public health, medicine, and health policy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	179
2	Public Health	8	8	199
3	Health Sciences	6	6	105
4	Engineering	1	1	17
5	Nursing	1	1	29

Rosa Rodríguez-Monguió

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Market withdrawal of new molecular entities approved in the United States from 1980 to 2009 Zaina P. Qureshi, Enrique Seoane‐Vazquez, Rosa Rodríguez-Monguió, Pharmacoepidemiology and Drug Safety	2011	152
Incentives for orphan drug research and development in the United States Enrique Seoane‐Vazquez, Rosa Rodríguez-Monguió, Sheryl L. Szeinbach, Orphanet Journal of Rare Diseases	2008	134
Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? Rosa Rodríguez-Monguió, T. Spargo, E. Seoane-Vazquez Orphanet Journal of Rare Diseases	2017	107
Racial disparities in the risk of developing obesity-related diseases: a cross-sectional study. Hong Zhang, Rosa Rodríguez-Monguió PubMed	2012	95
Using a Machine Learning System to Identify and Prevent Medication Prescribing Errors: A Clinical and Cost Analysis Evaluation Ronen Rozenblum, Rosa Rodríguez-Monguió, Lynn A. Volk, The Joint Commission Journal on Quality and Patient Safety Preventive MedicineClinical Decision Support SystemHealth PolicyCost Analysis EvaluationDrug Information System	2019	73
Innovation and competition in advanced therapy medicinal products Enrique Seoane‐Vazquez, Vaishali Shukla, Rosa Rodríguez-Monguió EMBO Molecular Medicine	2019	56
Priority review drugs approved by the <scp>FDA</scp> and the <scp>EMA</scp>: time for international regulatory harmonization of pharmaceuticals? Saad S. Alqahtani, Enrique Seoane‐Vazquez, Rosa Rodríguez-Monguió, Pharmacoepidemiology and Drug Safety	2015	39
Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals Jing Hao, Rosa Rodríguez-Monguió, Enrique Seoane‐Vazquez PLoS ONE	2015	36
Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes C.S. Kwon, Enrique Seoane‐Vazquez, Rosa Rodríguez-Monguió BMC Health Services Research	2018	32
Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980–2022 Enrique Seoane‐Vazquez, Rosa Rodríguez-Monguió, John H. Powers Scientific Reports	2024	31

Page 1